Michihisa Moriguchi

5PUBLICATIONS
45CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Te ariā o ngā tauira panoni hauora o te Māori (Māori theory of change models for health)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Feb 18, 2026
Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post-Progression Outcomes: A Multicenter Real-World Study in Advanced Hepatocellular Carcinoma.

Masanori Inoue, Sadahisa Ogasawara, Kazuhisa Asahara

|Nov 27, 2025
Impact of PNPLA3 Genotype on Hepatic Steatosis Response to Pemafibrate in MASLD With Dyslipidemia.

Takao Shirono, Yuya Seko, Seita Kataoka

|Nov 03, 2025
Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT.

Kazuomi Ueshima, Kaoru Tsuchiya, Tatsuya Yamashita

|Jun 05, 2024
Safety/efficacy of atezolizumab + bevacizumab during anti-platelet/anticoagulation therapy in unresectable hepatocellular carcinoma.

Michihisa Moriguchi, Keiichiro Okuda, Go Horiguchi

|Oct 05, 2023
A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study.

Kazufumi Kobayashi, Sadahisa Ogasawara, Susumu Maruta

Pageof 1

Frequent Collaborators

3 joint publications

Sadahisa Ogasawara

3 joint publications

Yuya Seko

2 joint publications

Naoya Kanogawa

2 joint publications

Masato Nakamura